Streetbeat News

Stock Prices

ALMS

BMY

JNJ

TAK

Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceutical company, has attracted attention from analysts at Guggenheim Partners and Cantor Fitzgerald. Both firms initiated coverage with positive ratings, citing the potential of Alumis' lead asset ESK-001 and its brain-penetrant TYK2 inhibitor A-005. Guggenheim set a price target of $32, while Cantor highlighted the company's modest valuation and commercial potential. Alumis recently raised $250 million through its IPO and private placement.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 7:18 pm

ON

Deep-pocketed investors have shown a bearish sentiment towards ON Semiconductor (NASDAQ:ON) through significant options activity. The majority of these trades are puts, indicating a potential decline in the stock price. Analysts have mixed ratings, with price targets ranging from $65 to $95.

Portfolio Pulse from Benzinga Insights

July 24, 2024 | 7:15 pm

Z

ZG

Zillow shares are trading lower following a decline in new home sales in June. Stocks across sectors are also down amid a broader selloff in tech.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:13 pm

VIGL

Vigil Neuroscience Inc. (NASDAQ:VIGL) released interim data from its Phase 1 clinical trial of VG-3927, a novel small molecule TREM2 agonist for treating Alzheimer's disease. The data showed positive safety, tolerability, and pharmacokinetic profiles, supporting further development. The stock rose 6.52% following the news.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 7:12 pm

ATUS

META

PINS

ROKU

SNAP

Shares of companies within the broader communication services sector are trading lower possibly in sympathy with overall market weakness.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:08 pm

BHC

Bausch Health shares are trading lower following an article suggesting potential bankruptcy, which the company has denied.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:05 pm

COST

NVR

WMT

Costco Wholesale Corp (NASDAQ:COST) is in prime stock-split territory with its share price trading above $800. The company's strong financial performance and recent growth make it a noteworthy candidate for a stock split, similar to Walmart Inc's (NYSE:WMT) recent 3-for-1 split. Despite not having split its stock since 2000, Costco's robust revenue growth and increased membership fees indicate confidence in continued growth.

Portfolio Pulse from Surbhi Jain

July 24, 2024 | 7:04 pm

GILD

Campaigners are urging Gilead Sciences Inc. to significantly reduce the price of its HIV prevention drug, lenacapavir, which is currently priced at $42,250 annually but could be produced for just $40. The drug, sold as Sunlenca, has shown 100% efficacy in preventing HIV in cisgender women in a Phase 3 trial. Gilead is awaiting further clinical trial data and regulatory approvals before pricing lenacapavir for prevention.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 7:04 pm

BITW

BLK

ETHE

Spot Ethereum ETFs had a strong first trading day, with significant inflows and trading volumes. Analysts are optimistic about Ethereum's price breaking its current consolidation and reaching new all-time highs. Major demand was noted for BlackRock's and Bitwise's products, while Grayscale saw outflows.

Portfolio Pulse from Khyathi Dalal

July 24, 2024 | 7:02 pm

AAPL

GOOG

GOOGL

Apple has launched a beta version of Apple Maps on the web, expanding its mapping service beyond iOS devices. This move could enhance Apple's ecosystem and compete more directly with Google Maps.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:02 pm